Literature DB >> 15928338

Slowing progression along the renal disease continuum.

Nelson P Kopyt1.   

Abstract

Patients in whom nephropathy develops as a result of hypertension or diabetes mellitus are more likely to die of cardiovascular disease (CVD) than of kidney disease. An early sign of impending nephropathy is microalbuminuria, defined as urinary excretion of albumin at a rate of 28.8 mg/24 h to 288 mg/24 h. Microalbuminuria is a marker of endothelial dysfunction, vascular injury, and renal disease and CVD, and it is associated with increased risk for myocardial infarction. Oxidative stress and endothelial dysfunction are unifying factors mediated by the renin-angiotensin system in renal disease and CVD. Clinical trials show reduced cardiovascular risk and a reversal of microalbuminuria with the use of agents that affect the renin-angiotensin system: angiotensin-receptor blockers in patients with type 2 diabetes mellitus and nephropathy, or angiotensin-converting enzyme inhibitors in patients with type 1 diabetes mellitus.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15928338

Source DB:  PubMed          Journal:  J Am Osteopath Assoc        ISSN: 0098-6151


  4 in total

1.  Effect of glycaemic control on glomerular filtration rate in diabetes mellitus patients.

Authors:  Allen Meeme; Hannington Kasozi
Journal:  Afr Health Sci       Date:  2009-08-01       Impact factor: 0.927

2.  Exploring metabolic dysfunction in chronic kidney disease.

Authors:  Adrian D Slee
Journal:  Nutr Metab (Lond)       Date:  2012-04-26       Impact factor: 4.169

Review 3.  Patient-Reported Outcomes in Patients with Chronic Kidney Disease and Kidney Transplant-Part 1.

Authors:  Evan Tang; Aarushi Bansal; Marta Novak; Istvan Mucsi
Journal:  Front Med (Lausanne)       Date:  2018-01-15

Review 4.  Use of sodium-glucose co-transporter-2 inhibitors in Asian patients with type 2 diabetes and kidney disease: An Asian perspective and expert recommendations.

Authors:  Chin Meng Khoo; Chaicharn Deerochanawong; Siew Pheng Chan; Bien Matawaran; Wayne Huey-Herng Sheu; Juliana Chan; Ambrish Mithal; Andrea Luk; Ketut Suastika; Kun-Ho Yoon; Linong Ji; Nguyen Huu Man; Carol Pollock
Journal:  Diabetes Obes Metab       Date:  2020-11-20       Impact factor: 6.577

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.